{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:40:10Z","timestamp":1733395210309,"version":"3.30.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00120-024-02446-9","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:03:07Z","timestamp":1729767787000},"page":"1285-1293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stadienabh\u00e4ngige Therapie des Seminoms","Stage-dependent treatment of seminomas"],"prefix":"10.1007","volume":"63","author":[{"given":"David","family":"Pfister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Seelemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"2446_CR1","unstructured":"B\u2011SNa BJK (2017) Epidemiologie b\u00f6sartiger Hodentumoren in Deutschland. Onkologe: 2390\u20132396"},{"issue":"4","key":"2446_CR2","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/j.clgc.2017.01.012","volume":"15","author":"DV Matei","year":"2017","unstructured":"Matei\u00a0DV, Vartolomei\u00a0MD, Renne\u00a0G, Tringali\u00a0VML, Russo\u00a0A, Bianchi\u00a0R et\u00a0al (2017) Reliability of Frozen Section Examination in a\u00a0Large Cohort of Testicular Masses: What Did We Learn? Clin Genitourin Cancer 15(4):e689\u2013e96","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2446_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.juro.2018.03.007","volume":"200","author":"P Paffenholz","year":"2018","unstructured":"Paffenholz\u00a0P, Held\u00a0L, Loosen\u00a0SH, Pfister\u00a0D, Heidenreich\u00a0A (2018) Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. J\u00a0Urol 200(2):353\u2013360","journal-title":"J Urol"},{"key":"2446_CR4","unstructured":"EAU (2018) EAU Guidlines on testicular cancer. Eur Assiciation Urol"},{"issue":"22","key":"2446_CR5","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","volume":"20","author":"P Warde","year":"2002","unstructured":"Warde\u00a0P, Specht\u00a0L, Horwich\u00a0A, Oliver\u00a0T, Panzarella\u00a0T, Gospodarowicz\u00a0M et\u00a0al (2002) Prognostic factors for relapse in stage\u00a0I seminoma managed by surveillance: a\u00a0pooled analysis. J\u00a0Clin Oncol 20(22):4448\u20134452","journal-title":"J Clin Oncol"},{"issue":"3","key":"2446_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","volume":"73","author":"JL Boormans","year":"2018","unstructured":"Boormans\u00a0JL, Mayor de Castro\u00a0J, Marconi\u00a0L, Yuan\u00a0Y, Laguna Pes\u00a0MP, Bokemeyer\u00a0C et\u00a0al (2018) Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage\u00a0I Seminoma Testis Patients Under Surveillance: a\u00a0Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol 73(3):394\u2013405","journal-title":"Eur Urol"},{"key":"2446_CR7","doi-asserted-by":"crossref","unstructured":"Boormans JL, Sylvester R, Anson-Cartwright L, Glicksman RM, Hamilton RJ, Hahn E et\u00a0al (2023) Prognostic Factor Risk Groups for Clinical Stage\u00a0I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol","DOI":"10.1016\/j.euo.2023.10.014"},{"issue":"1","key":"2446_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.23.00959","volume":"42","author":"T Wagner","year":"2024","unstructured":"Wagner\u00a0T, Toft\u00a0BG, Lauritsen\u00a0J, Bandak\u00a0M, Christensen\u00a0IJ, Engvad\u00a0B et\u00a0al (2024) Prognostic Factors for Relapse in Patients With Clinical Stage\u00a0I Testicular Seminoma: A\u00a0Nationwide, Population-Based Cohort Study. J\u00a0Clin Oncol 42(1):81\u201389","journal-title":"J Clin Oncol"},{"issue":"12","key":"2446_CR9","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s00345-022-04145-6","volume":"40","author":"CG Ruf","year":"2022","unstructured":"Ruf\u00a0CG, Schmidt\u00a0S, Kliesch\u00a0S, Oing\u00a0C, Pfister\u00a0D, Busch\u00a0J et\u00a0al (2022) Testicular germ cell tumours\u2019 clinical stage\u00a0I:\u00a0comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival\u2011a systematic review. World J Urol 40(12):2889\u20132900","journal-title":"World J Urol"},{"issue":"6","key":"2446_CR10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.2005.08.003","volume":"23","author":"WG Jones","year":"2005","unstructured":"Jones\u00a0WG, Fossa\u00a0SD, Mead\u00a0GM, Roberts\u00a0JT, Sokal\u00a0M, Horwich\u00a0A et\u00a0al (2005) Randomized trial of 30 versus 20\u202fGy in the adjuvant treatment of stage\u00a0I Testicular Seminoma: a\u00a0report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J\u00a0Clin Oncol 23(6):1200\u20131208","journal-title":"J Clin Oncol"},{"issue":"1","key":"2446_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2013.551","volume":"110","author":"A Horwich","year":"2014","unstructured":"Horwich\u00a0A, Fossa\u00a0SD, Huddart\u00a0R, Dearnaley\u00a0DP, Stenning\u00a0S, Aresu\u00a0M et\u00a0al (2014) Second cancer risk and mortality in men treated with radiotherapy for stage\u00a0I seminoma. Br J Cancer 110(1):256\u2013263","journal-title":"Br J Cancer"},{"issue":"8","key":"2446_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","volume":"29","author":"RT Oliver","year":"2011","unstructured":"Oliver\u00a0RT, Mead\u00a0GM, Rustin\u00a0GJ, Joffe\u00a0JK, Aass\u00a0N, Coleman\u00a0R et\u00a0al (2011) Randomized trial of carboplatin versus radiotherapy for stage\u00a0I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214). J\u00a0Clin Oncol 29(8):957\u2013962","journal-title":"J Clin Oncol"},{"issue":"7","key":"2446_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00432-016-2162-z","volume":"142","author":"KP Dieckmann","year":"2016","unstructured":"Dieckmann\u00a0KP, Dralle-Filiz\u00a0I, Matthies\u00a0C, Heinzelbecker\u00a0J, Bedke\u00a0J, Ellinger\u00a0J et\u00a0al (2016) Testicular seminoma clinical stage\u00a01: treatment outcome on a\u00a0routine care level. J\u00a0Cancer Res Clin Oncol 142(7):1599\u20131607","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2446_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/annonc\/mdm540","volume":"19","author":"T Powles","year":"2008","unstructured":"Powles\u00a0T, Robinson\u00a0D, Shamash\u00a0J, Moller\u00a0H, Tranter\u00a0N, Oliver\u00a0T (2008) The long-term risks of adjuvant carboplatin treatment for stage\u00a0I seminoma of the testis. Ann Oncol : Off J Eur Soc Med Oncol 19(3):443\u2013447","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"11","key":"2446_CR15","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s12094-017-1742-y","volume":"19","author":"A Terbuch","year":"2017","unstructured":"Terbuch\u00a0A, Posch\u00a0F, Annerer\u00a0LM, Bauernhofer\u00a0T, Pichler\u00a0M, Szkandera\u00a0J et\u00a0al (2017) Long-term cardiovascular complications in stage\u00a0I seminoma patients. Clin Transl Oncol 19(11):1400\u20131408","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"2446_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cncr.30458","volume":"123","author":"MS Mortensen","year":"2017","unstructured":"Mortensen\u00a0MS, Bandak\u00a0M, Kier\u00a0MG, Lauritsen\u00a0J, Agerbaek\u00a0M, Holm\u00a0NV et\u00a0al (2017) Surveillance versus adjuvant radiotherapy for patients with high-risk stage\u00a0I seminoma. Cancer 123(7):1212\u20131218","journal-title":"Cancer"},{"issue":"7","key":"2446_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","volume":"27","author":"T Tandstad","year":"2016","unstructured":"Tandstad\u00a0T, Stahl\u00a0O, Dahl\u00a0O, Haugnes\u00a0HS, Hakansson\u00a0U, Karlsdottir\u00a0A et\u00a0al (2016) Treatment of stage\u00a0I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a\u00a0report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol : Off J Eur Soc Med Oncol 27(7):1299\u20131304","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"22","key":"2446_CR18","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1200\/JCO.21.01199","volume":"40","author":"JK Joffe","year":"2022","unstructured":"Joffe\u00a0JK, Cafferty\u00a0FH, Murphy\u00a0L, Rustin\u00a0GJS, Sohaib\u00a0SA, Gabe\u00a0R et\u00a0al (2022) Imaging Modality and Frequency in Surveillance of Stage\u00a0I Seminoma Testicular Cancer: Results From a\u00a0Randomized, Phase\u00a0III, Noninferiority Trial (TRISST). J\u00a0Clin Oncol 40(22):2468\u20132478","journal-title":"J Clin Oncol"},{"issue":"1","key":"2446_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","volume":"33","author":"C Kollmannsberger","year":"2015","unstructured":"Kollmannsberger\u00a0C, Tandstad\u00a0T, Bedard\u00a0PL, Cohn-Cedermark\u00a0G, Chung\u00a0PW, Jewett\u00a0MA et\u00a0al (2015) Patterns of relapse in patients with clinical stage\u00a0I testicular cancer managed with active surveillance. J\u00a0Clin Oncol 33(1):51\u201357","journal-title":"J Clin Oncol"},{"key":"2446_CR20","doi-asserted-by":"publisher","first-page":"8671832","DOI":"10.1155\/2018\/8671832","volume":"2018","author":"C Fung","year":"2018","unstructured":"Fung\u00a0C, Dinh\u00a0P Jr., Ardeshir-Rouhani-Fard\u00a0S, Schaffer\u00a0K, Fossa\u00a0SD, Travis\u00a0LB (2018) Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Adv Urol 2018:8671832","journal-title":"Adv Urol"},{"issue":"6","key":"2446_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","volume":"29","author":"T Tandstad","year":"2011","unstructured":"Tandstad\u00a0T, Smaaland\u00a0R, Solberg\u00a0A, Bremnes\u00a0RM, Langberg\u00a0CW, Laurell\u00a0A et\u00a0al (2011) Management of seminomatous testicular cancer: a\u00a0binational prospective population-based study from the Swedish norwegian testicular cancer study group. J\u00a0Clin Oncol 29(6):719\u2013725","journal-title":"J Clin Oncol"},{"issue":"16","key":"2446_CR22","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.22.00624","volume":"41","author":"S Daneshmand","year":"2023","unstructured":"Daneshmand\u00a0S, Cary\u00a0C, Masterson\u00a0T, Einhorn\u00a0L, Adra\u00a0N, Boorjian\u00a0SA et\u00a0al (2023) Surgery in Early Metastatic Seminoma: A\u00a0Phase\u00a0II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J\u00a0Clin Oncol 41(16):3009\u20133018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2446_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.euo.2023.06.004","volume":"7","author":"A Heidenreich","year":"2024","unstructured":"Heidenreich\u00a0A, Paffenholz\u00a0P, Hartmann\u00a0F, Seelemeyer\u00a0F, Pfister\u00a0D (2024) Retroperitoneal Lymph Node Dissection in Clinical Stage IIA\/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol 7(1):122\u2013127","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"2446_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","volume":"84","author":"A Hiester","year":"2023","unstructured":"Hiester\u00a0A, Che\u00a0Y, Lusch\u00a0A, Kuss\u00a0O, Niegisch\u00a0G, Lorch\u00a0A et\u00a0al (2023) Phase\u00a02 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA\/B (PRIMETEST). Eur Urol 84(1):25\u201331","journal-title":"Eur Urol"},{"issue":"1","key":"2446_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000003697","volume":"211","author":"RS Matulewicz","year":"2024","unstructured":"Matulewicz\u00a0RS, Benfante\u00a0N, Funt\u00a0SA, Feldman\u00a0DR, Carver\u00a0B, Doudt\u00a0A et\u00a0al (2024) Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. J\u00a0Urol 211(1):80\u201389","journal-title":"J Urol"},{"issue":"23","key":"2446_CR26","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1200\/JCO.22.01822","volume":"41","author":"I Tachibana","year":"2023","unstructured":"Tachibana\u00a0I, Alabd\u00a0A, Tong\u00a0Y, Piroozi\u00a0A, Mahmoud\u00a0M, Kern\u00a0SQ et\u00a0al (2023) Primary Retroperitoneal Lymph Node Dissection for Stage\u00a0II Seminoma: Is Surgery the New Path Forward? J\u00a0Clin Oncol 41(23):3930\u20133938","journal-title":"J Clin Oncol"},{"issue":"6","key":"2446_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","volume":"21","author":"J Classen","year":"2003","unstructured":"Classen\u00a0J, Schmidberger\u00a0H, Meisner\u00a0C, Souchon\u00a0R, Sautter-Bihl\u00a0ML, Sauer\u00a0R et\u00a0al (2003) Radiotherapy for stages IIA\/B testicular seminoma: final report of a\u00a0prospective multicenter clinical trial. J\u00a0Clin Oncol 21(6):1101\u20131106","journal-title":"J Clin Oncol"},{"issue":"4","key":"2446_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/annonc\/mdu447","volume":"26","author":"P Giannatempo","year":"2015","unstructured":"Giannatempo\u00a0P, Greco\u00a0T, Mariani\u00a0L, Nicolai\u00a0N, Tana\u00a0S, Fare\u00a0E et\u00a0al (2015) Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a\u00a0systematic review and meta-analysis of patient outcomes. Ann Oncol : Off J Eur Soc Med Oncol 26(4):657\u2013668","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"2","key":"2446_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.eururo.2022.04.031","volume":"82","author":"Y Loriot","year":"2022","unstructured":"Loriot\u00a0Y, Texier\u00a0M, Culine\u00a0S, Flechon\u00a0A, Thiery-Vuillemin\u00a0A, Gravis\u00a0G, The GETUG SEMITEP Trial et\u00a0al (2022) De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography. Eur Urol 82(2):172\u2013179","journal-title":"Eur Urol"},{"issue":"11","key":"2446_CR30","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","volume":"23","author":"A Papachristofilou","year":"2022","unstructured":"Papachristofilou\u00a0A, Bedke\u00a0J, Hayoz\u00a0S, Schratzenstaller\u00a0U, Pless\u00a0M, Hentrich\u00a0M et\u00a0al (2022) Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet Oncol 23(11):1441\u20131450","journal-title":"Lancet Oncol"},{"issue":"5","key":"2446_CR31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","volume":"15","author":"R de Wit","year":"1997","unstructured":"de Wit\u00a0R, Stoter\u00a0G, Kaye\u00a0SB, Sleijfer\u00a0DT, Jones\u00a0WG, ten Bokkel Huinink\u00a0WW et\u00a0al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a\u00a0randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J\u00a0Clin Oncol 15(5):1837\u20131843","journal-title":"J Clin Oncol"},{"issue":"5","key":"2446_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1586\/14737140.5.5.869","volume":"5","author":"ML Quek","year":"2005","unstructured":"Quek\u00a0ML, Simma-Chiang\u00a0V, Stein\u00a0JP, Pinski\u00a0J, Quinn\u00a0DI, Skinner\u00a0DG (2005) Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther 5(5):869\u2013874","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5S","key":"2446_CR33","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/01.JU.0001008660.87408.90.18","volume":"211","author":"ASS Ghoreifi","year":"2024","unstructured":"Ghoreifi\u00a0ASS, Sheybaee\u00a0F et\u00a0al (2024) Post-chemotherapy retroperoitoneal lymph node dissection for testicular seminoma: experience from two large referral centers. J\u00a0Urol 211(5S):e9","journal-title":"J Urol"},{"issue":"6","key":"2446_CR34","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1097\/01.ju.0000060121.33899.4b","volume":"169","author":"AA Mosharafa","year":"2003","unstructured":"Mosharafa\u00a0AA, Foster\u00a0RS, Leibovich\u00a0BC, Bihrle\u00a0R, Johnson\u00a0C, Donohue\u00a0JP (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J\u00a0Urol 169(6):2126\u20132128","journal-title":"J Urol"},{"issue":"10","key":"2446_CR35","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s00120-014-3708-9","volume":"54","author":"D Pfister","year":"2015","unstructured":"Pfister\u00a0D, Porres\u00a0D, Matveev\u00a0V, Heidenreich\u00a0A (2015) Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urol Ausg\u00a0A 54(10):1402\u20131406","journal-title":"Urol Ausg A"},{"issue":"6","key":"2446_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","volume":"22","author":"M De Santis","year":"2004","unstructured":"De Santis\u00a0M, Becherer\u00a0A, Bokemeyer\u00a0C, Stoiber\u00a0F, Oechsle\u00a0K, Sellner\u00a0F et\u00a0al (2004) 2\u201118fluoro-deoxy-D-glucose positron emission tomography is a\u00a0reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J\u00a0Clin Oncol 22(6):1034\u20131039","journal-title":"J Clin Oncol"},{"key":"2446_CR37","doi-asserted-by":"crossref","unstructured":"Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F et\u00a0al Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J\u00a0Clin Oncol 2018:JCO1800210","DOI":"10.1200\/JCO.18.00210"},{"issue":"2","key":"2446_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1078-0432.CCR-23-0730","volume":"30","author":"G Belge","year":"2024","unstructured":"Belge\u00a0G, Dumlupinar\u00a0C, Nestler\u00a0T, Klemke\u00a0M, Torzsok\u00a0P, Trenti\u00a0E et\u00a0al (2024) Detection of Recurrence through microRNA-371a\u20133p Serum Levels in a\u00a0Follow-up of Stage\u00a0I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res 30(2):404\u2013412","journal-title":"Clin Cancer Res"},{"key":"2446_CR39","doi-asserted-by":"crossref","unstructured":"Seelemeyer F, Pfister D, Pappesch R, Merkelbach-Bruse S, Paffenholz P, Heidenreich A (2023) Evaluation of a\u00a0miRNA-371a\u20133p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA\/B Seminoma or Nonseminoma. Eur Urol Oncol","DOI":"10.1016\/S0302-2838(23)00791-1"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02446-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:03:49Z","timestamp":1733303029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02446-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"2 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.\u00a0Pfister<\/b>:\u00a0A. Finanzielle Interessen: Reise: Janssen, Bayer\u00a0\u2013 Berater: MSD, AstraZeneca, Pfizer, Referent: Janssen.\u00a0\u2013 B. Nichtfinanzielle Interessen: angestellter Urologe, Klinik f\u00fcr Urologie, Uro-Onkologie, spezielle urologische und Roboter-assistierte Chirurgie | Universit\u00e4tsklinikum K\u00f6ln (A\u00d6R), Kerpener Str.\u00a062, 50937 K\u00f6ln | Mitgliedschaften: DGU, EAU, CAU. <b>C.\u00a0Rieger<\/b>: A.\u00a0Finanzielle Interessen: C.\u00a0Rieger gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Klinik f\u00fcr Urologie, Universit\u00e4tsklinik K\u00f6ln | Mitgliedschaften: DGRU, DGU. <b>F.\u00a0Seelemeyer<\/b>: A.\u00a0Finanzielle Interessen: F.\u00a0Seelemeyer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt in der Klinik f\u00fcr Urologie, Uniklinik K\u00f6ln | Mitgliedschaften: DGU, GESRU, EAU. <b>A.\u00a0Heidenreich<\/b>: A.\u00a0Finanzielle Interessen: A.\u00a0Heidenreich gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik f\u00fcr Urologie, Uniklinik K\u00f6ln | Mitgliedschaften: AUA, ASCO, DGU, DGHO, EAU, ESMO, SIO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}